학술논문
Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Document Type
Article
Source
European Journal of Preventive Cardiology; Jun2023, Vol. 30 Issue 8, p634-643, 10p
Subject
Language
ISSN
20474873